Experts developed consensus recommendations through the modified Delphi process for metastatic prostate cancer management ...

Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate ...

Docetaxel plus prednisone as a first-line chemotherapy ... The identification of new drug resistance mechanisms and prostate cancer molecular subtypes based on genomic and proteomic analysis ...

and a corticosteroid as a first-line therapy for metastatic castration-resistant prostate cancer (mCRPC). However, the panel agreed with the FDA reviewer’s position that the regimen had not yet ...

Men with metastatic castration-resistant prostate cancer (mCRPC ... use of drugs known to reduce ICI efficacy, such as steroids and antibiotics. "Considering the prevailing negativity of multiple ...

Prostate cancer that has spread to other parts of the body has limited treatment options, but a biomedical research group affiliated with Main Line Health has begun investigating a new therapy for ...

Bangalore: AstraZeneca Pharma India Limited has surrendered its marketing authorisation for Olaparib film-coated tablets ...